Paul Thevenot

4.6k total citations · 2 hit papers
57 papers, 3.5k citations indexed

About

Paul Thevenot is a scholar working on Hepatology, Epidemiology and Biomedical Engineering. According to data from OpenAlex, Paul Thevenot has authored 57 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Hepatology, 13 papers in Epidemiology and 12 papers in Biomedical Engineering. Recurrent topics in Paul Thevenot's work include Hepatocellular Carcinoma Treatment and Prognosis (12 papers), Liver Disease Diagnosis and Treatment (12 papers) and Bone Tissue Engineering Materials (8 papers). Paul Thevenot is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (12 papers), Liver Disease Diagnosis and Treatment (12 papers) and Bone Tissue Engineering Materials (8 papers). Paul Thevenot collaborates with scholars based in United States, Australia and Spain. Paul Thevenot's co-authors include Liping Tang, Wenjing Hu, David W. Baker, John W. Eaton, Ashwin Nair, Paulo C. Rodrı́guez, Patrick Raber, Rosa A. Sierra, Augusto C. Ochoa and Jinhui Shen and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Immunity.

In The Last Decade

Paul Thevenot

53 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Surface Chemistry Influences Implant Biocompatibility

2008 615 citations Liping Tang, Paul Thevenot et al. profile →
Nanomaterial cytotoxicity is composition, size, and cell type dependent

2010 523 citations Paul Thevenot, Liping Tang et al. profile →

Peers

Countries citing papers authored by Paul Thevenot

Since Specialization

Citations

This map shows the geographic impact of Paul Thevenot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Thevenot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Thevenot more than expected).

Fields of papers citing papers by Paul Thevenot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Thevenot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Thevenot. The network helps show where Paul Thevenot may publish in the future.

Co-authorship network of co-authors of Paul Thevenot

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Thevenot. A scholar is included among the top collaborators of Paul Thevenot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Thevenot. Paul Thevenot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Contemporary Clinical Utilization of Radioembolization with Immune Checkpoint Inhibitors as First-Line Treatment in HCC: Real-World Report on Safety and Outcomes 2025 ·Cancers ·(unknown), Tyler Sandow, (unknown), (unknown), Juan Gimenez, Humberto Bohórquez, Ari Cohen, Jonathan Mizrahi, Lingling Du, Paul Thevenot	0
2	Using Voxel-Based Dosimetry to Evaluate Sphere Concentration and Tumor Dose in Hepatocellular Carcinoma Treated with Yttrium-90 Radiation Segmentectomy with Glass Microspheres 2024 ·Journal of Vascular and Interventional Radiology ·Tyler Sandow, Juan Gimenez, (unknown), (unknown), Patrick Gilbert, (unknown), (unknown), Kirk Fowers, Ari Cohen, Paul Thevenot	5
3	Imaging Delay Following Liver-Directed Therapy Increases Progression Risk in Early- to Intermediate-Stage Hepatocellular Carcinoma 2024 ·Cancers ·(unknown), (unknown), Tyler Sandow, Juan Gimenez, Daniel Fort, (unknown), Ari Cohen, Paul Thevenot	1
4	Yttrium-90 Induces an Effector Memory Response with Neoantigen Clonotype Expansion: Implications for Immunotherapy 2024 ·Cancer Research Communications ·(unknown), Tyler Sandow, (unknown), (unknown), Ari Cohen, Paul Thevenot	1
5	A Single-Step Immunocapture Assay to Quantify HCC Exosomes Using the Highly Sensitive Fluorescence Nanoparticle-Tracking Analysis 2023 ·Journal of Hepatocellular Carcinoma ·(unknown), (unknown), Yücel Aydın, (unknown), Tyler Sandow, (unknown), Martin Moehlen, Paul Thevenot, Ari Cohen, Srikanta Dash	9
6	Exosome Shedding Is Concordant with Objective Treatment Response Rate and Stratifies Time to Progression in Treatment Naïve, Non-Resectable Hepatocellular Carcinoma 2023 ·SHILAP Revista de lepidopterología ·(unknown), Dorota Wyczechowska, (unknown), Tyler Sandow, Juan Gimenez, Ali Rıza Köksal, Yücel Aydın, Srikanta Dash, Ari Cohen, Paul Thevenot	1
7	α-Fetoprotein, α-Fetoprotein-L3, and Des-γ-Carboxy Prothrombin Stratify Hepatocellular Carcinoma Treatment Response and Progression Risk 2023 ·SHILAP Revista de lepidopterología ·(unknown), Michael Schneider, Tyler Sandow, Juan Gimenez, (unknown), Daniel Fort, Ari Cohen, Paul Thevenot	2
8	Hypoalbuminemia Is a Hepatocellular Carcinoma Independent Risk Factor for Tumor Progression in Low-Risk Bridge to Transplant Candidates 2022 ·Cancers ·(unknown), Tyler Sandow, Jai V. Patel, (unknown), Daniel Fort, Ari Cohen, Paul Thevenot	7
9	Baseline Alpha-Fetoprotein, Alpha-Fetoprotein-L3, and Des-Gamma-Carboxy Prothrombin Biomarker Status in Bridge to Liver Transplant Outcomes for Hepatocellular Carcinoma 2021 ·Cancers ·(unknown), Tyler Sandow, Daniel Fort, Jai V. Patel, (unknown), Ian Carmody, Ari Cohen, Paul Thevenot	10
10	Interleukin-33 / Cyclin D1 imbalance in severe liver steatosis predicts susceptibility to ischemia reperfusion injury 2019 ·PLoS ONE ·(unknown), Anderson R. Frank, (unknown), (unknown), Kim R. Bridle, Dorothy H. Crawford, John Seal, (unknown), Himanshu Vashistha, Paul Thevenot, Ari Cohen	6
11	PRE-TREATMENT LYMPHOCYTE STATUS IN HCC PATIENTS ASSOCIATES WITH DEB-TACE RESPONSE AND CORRELATES WITH LIVER SYNTHETIC DYSFUNCTION AND INCREASED REGULATORY IMMUNE CELLS 2019 ·Hepatology ·(unknown), Tyler Sandow, (unknown), Paul Thevenot, Ari Cohen	2
12	Complement Activation in Liver Transplantation: Role of Donor Macrosteatosis and Implications in Delayed Graft Function 2018 ·International Journal of Molecular Sciences ·(unknown), Paul Thevenot, (unknown), Ari Cohen	14
13	l -Arginine Depletion Blunts Antitumor T-cell Responses by Inducing Myeloid-Derived Suppressor Cells 2014 ·Cancer Research ·Matthew Fletcher, María E. Ramírez, Rosa A. Sierra, Patrick Raber, Paul Thevenot, Amir A. Al-Khami, (unknown), Claudia Hernandez, Dorota Wyczechowska, Augusto C. Ochoa, Paulo C. Rodrı́guez	219
14	Rescue of Notch-1 Signaling in Antigen-Specific CD8+ T Cells Overcomes Tumor-Induced T-cell Suppression and Enhances Immunotherapy in Cancer 2014 ·Cancer Immunology Research ·Rosa A. Sierra, Paul Thevenot, Patrick Raber, Yan Cui, Chris Parsons, Augusto C. Ochoa, Jimena Trillo-Tinoco, Luis Del Valle, Paulo C. Rodrı́guez	66
15	Subpopulations of myeloid‐derived suppressor cells impair T cell responses through independent nitric oxide‐related pathways 2013 ·International Journal of Cancer ·Patrick Raber, Paul Thevenot, Rosa A. Sierra, Dorota Wyczechowska, (unknown), María E. Ramírez, Augusto C. Ochoa, Matthew Fletcher, Cruz Velasco, Anna Wilk, Krzysztof Reiss, Paulo C. Rodrı́guez	243
16	Radical-Containing Ultrafine Particulate Matter Initiates Epithelial-to-Mesenchymal Transitions in Airway Epithelial Cells 2013 ·American Journal of Respiratory Cell and Molecular Biology ·Paul Thevenot, Jordy Saravia, Nili Jin, (unknown), (unknown), (unknown), M Kelley, Valeria Y. Hebert, Barry Dellinger, Tammy R. Dugas, Francesco J. DeMayo, Stephania A. Cormier	95
17	Early-life exposure to combustion-derived particulate matter causes pulmonary immunosuppression 2013 ·Mucosal Immunology ·Jordy Saravia, (unknown), Paul Thevenot, (unknown), Bishwas Shrestha, Slawo Lomnicki, Stephania A. Cormier	55
18	Novel Polymeric Scaffolds Using Protein Microbubbles as Porogen and Growth Factor Carriers 2009 ·Tissue Engineering Part C Methods ·Ashwin Nair, Paul Thevenot, Jagannath Dey, Jinhui Shen, (unknown), Jian Yang, Liping Tang	39
19	Method to Analyze Three-Dimensional Cell Distribution and Infiltration in Degradable Scaffolds 2008 ·Tissue Engineering Part A ·Paul Thevenot, Ashwin Nair, Jagannath Dey, Jian Yang, Liping Tang	8
20	Method to Analyze Three-Dimensional Cell Distribution and Infiltration in Degradable Scaffolds 2008 ·Tissue Engineering Part C Methods ·Paul Thevenot, Ashwin Nair, Jagannath Dey, Jian Yang, Liping Tang	147

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact